Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)

17.46
+0.06
+(0.34%)
At close: 3:00:01 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
26,539,247.21
24,531,390.15
21,248,086.69
16,759,335.26
14,582,865.28
Cost of Revenue
17,457,309.22
15,724,070
13,216,857.74
10,365,747.80
8,973,435.15
Gross Profit
9,081,938
8,807,320.15
8,031,228.96
6,393,587.46
5,609,430.13
Operating Expense
7,592,271.41
6,892,803.92
6,366,340.50
5,198,707.22
4,162,619.71
Operating Income
1,489,666.58
1,914,516.23
1,664,888.45
1,194,880.24
1,446,810.42
Net Non Operating Interest Income Expense
-189,862.12
-190,146.01
-207,612.26
-137,926.08
11,052.92
Pretax Income
1,216,742.69
1,627,785.05
1,414,894.61
1,043,912.66
1,446,410.33
Tax Provision
294,627.63
397,123.82
335,621.39
239,517.97
363,390.86
Net Income Common Stockholders
850,262.81
1,166,498.18
1,035,723.83
791,230.98
1,062,181.10
Basic EPS
0.75
1.03
0.91
0.70
0.94
Diluted EPS
0.75
1.03
0.91
0.70
0.94
Basic Average Shares
1,135,530.21
1,132,522.51
1,138,158.06
1,130,329.97
1,132,993.18
Diluted Average Shares
1,135,530.21
1,132,522.51
1,138,158.06
1,130,329.97
1,132,993.18
Total Operating Income as Reported
1,214,034.83
1,631,843.07
1,420,794.36
1,040,533.76
1,447,962.14
Rent Expense Supplemental
--
38,302.32
42,689.67
37,369.60
21,790.80
Total Expenses
25,049,580.63
22,616,873.92
19,583,198.24
15,564,455.03
13,136,054.86
Net Income from Continuing & Discontinued Operation
850,262.81
1,166,498.18
1,035,723.83
791,230.98
1,062,181.10
Normalized Income
917,351.78
1,241,411.58
1,067,986.51
786,271.30
1,083,193.30
Interest Income
77,871.99
85,192.19
63,077.08
68,270.44
49,531.02
Interest Expense
60,121.86
66,219.30
48,234.86
179,759.04
11,497.39
Net Interest Income
-189,862.12
-190,146.01
-207,612.26
-137,926.08
11,052.92
EBIT
1,276,864.55
1,694,004.35
1,463,129.47
1,223,671.70
1,457,907.72
EBITDA
1,276,864.55
3,141,618.66
2,751,246.18
2,372,855.85
1,628,679.71
Reconciled Cost of Revenue
17,457,309.22
15,724,070
13,216,857.74
10,365,747.80
8,973,435.15
Reconciled Depreciation
--
1,447,614.31
1,288,116.71
1,149,184.15
170,771.99
Net Income from Continuing Operation Net Minority Interest
850,262.81
1,166,498.18
1,035,723.83
791,230.98
1,062,181.10
Total Unusual Items Excluding Goodwill
-88,524.76
-99,087.31
-42,295.39
6,436.48
-28,062.52
Total Unusual Items
-88,524.76
-99,087.31
-42,295.39
6,436.48
-28,062.52
Normalized EBITDA
1,365,389.31
3,240,705.97
2,793,541.57
2,366,419.37
1,656,742.23
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-21,435.79
-24,173.91
-10,032.72
1,476.80
-7,050.33
12/31/2020 - 7/31/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1OT.F Ovid Therapeutics Inc.
0.2260
+15.31%
 
RXK3.F SELLAS Life Sciences Group, Inc.
1.1500
-2.21%
 
1VT.MU Viking Therapeutics Inc
22.61
+1.10%
 
EXOZ eXoZymes, Inc.
13.09
-3.25%
 
AVBP ArriVent BioPharma, Inc.
20.82
-1.23%
 
RAPP Rapport Therapeutics, Inc.
11.19
-1.64%
 
MBX MBX Biosciences, Inc.
9.49
+5.46%
 
DSGN Design Therapeutics, Inc.
4.0900
+0.49%
 
SEPN Septerna, Inc.
6.21
+1.06%
 
ACXP Acurx Pharmaceuticals, Inc.
0.3914
+1.14%